Patents Represented by Attorney, Agent or Law Firm Brian P. Barrett
  • Process to make .alpha.,.alpha.-difluoro-.beta.-hydroxyl thiol esters
    Patent number: 5756775
    Abstract: A process to make .alpha.,.alpha.-difluoro-.beta.-hydroxy thiol esters of formula (IIIA) ##STR1## comprising reacting a difluoroethanethioate of formula (IVA) ##STR2## with a second reactant selected from the group consisting of aldehydes, ketones, acid halides and esters; in a solvent and in the presence of a strong base; with the proviso that the process is conducted in the absence of a catalyst and in the absence of a silyl containing compound. These thiol esters are useful as intermediates in organic syntheses of pharmaceutical products.
    Type: Grant
    Filed: December 9, 1996
    Date of Patent: May 26, 1998
    Assignee: Eli Lilly and Company
    Inventor: John A. Weigel
  • Stereoselective anion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
    Patent number: 5744597
    Abstract: A stereoselective anion glycosylation process for preparing beta- and alpha-anomer enriched 2', 2'-difluoro-2'-deoxynucleosides and 2'-deoxy-2'-fluoronucleosides by reacting an alpha- or beta-anomer enriched 2-deoxy-2-fluorocarbohydrate or 2-deoxy-2,2-difluorocarbohydrate with at least a molar equivalent of a salt of a nucleobase derivative in an inert solvent.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: April 28, 1998
    Assignee: Eli Lilly and Company
    Inventors: Ta-Sen Chou, Cora S. Grossman, Larry Wayne Hertel, Richard E. Holmes, Charles D. Jones, Thomas E. Mabry
  • Benzo?f!quinolinones
    Patent number: 5710163
    Abstract: This invention relates to hexa- and octahydrobenzo?f!quinolin-3-ones, pharmaceutical formulations containing those compounds and methods of their use as steroid 5.alpha.-reductase inhibitors.
    Type: Grant
    Filed: July 17, 1996
    Date of Patent: January 20, 1998
    Assignee: Eli Lilly and Company
    Inventor: James E. Audia
  • Angiotensin II antagonists
    Patent number: 5693633
    Abstract: This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: December 2, 1997
    Assignee: Eli Lilly and Company
    Inventors: Donald B. Boyd, Sherryl L. Lifer, Winston S. Marshall, Alan D. Palkowitz, William Pfeifer, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, K. Jeff Thrasher, Venkatraghavan Vasudevan, Celia A. Whitesitt
  • Benzo ?F! quinolinones
    Patent number: 5670512
    Abstract: This invention relates to hexa- and octaahydrobenzo?f!quinolin-3-ones, pharmaceutical formulations containing those compounds and methods of their use as steroid 5.alpha.-reductase inhibitors.
    Type: Grant
    Filed: April 17, 1996
    Date of Patent: September 23, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Kenneth S. Hirsch, Charles D. Jones, David E. Lawhorn, Loretta A. McQuaid, Leland O. Weigel
  • Treatment and prevention of prostatic cancer metastasis
    Patent number: 5635197
    Abstract: A series of benzoquinolin-3-ones are pharmaceuticals effective in preventing the development of prostatic cancer, or preventing or treating the metastasis to bone of prostatic cancer.
    Type: Grant
    Filed: March 21, 1995
    Date of Patent: June 3, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Blake L. Neubauer
  • Method of preventing prostatic cancer development
    Patent number: 5629007
    Abstract: A series of benzoquinolin-3-ones are pharmaceuticals effective in preventing the development of prostatic cancer, or preventing or treating the metastasis to bone of prostatic cancer.
    Type: Grant
    Filed: March 21, 1995
    Date of Patent: May 13, 1997
    Assignee: ELi Lilly and Company
    Inventors: James E. Audia, Blake L. Neubauer
  • 5.alpha.-reductase inhibitors
    Patent number: 5622961
    Abstract: A series of benzoquinolin-3-ones are pharmaceuticals effective in treating conditions consequent on both Type I and Type II 5.alpha.-reductase.
    Type: Grant
    Filed: May 11, 1995
    Date of Patent: April 22, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Loretta A. McQuaid, Blake L. Neubauer, Vincent P. Rocco
  • 5.alpha.-reductase inhibitors
    Patent number: 5622962
    Abstract: A series of benzoquinolin-3-ones are pharmaceuticals effective in treating conditions consequent on both Type I and Type II 5.alpha.-reductase.
    Type: Grant
    Filed: May 11, 1995
    Date of Patent: April 22, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Loretta A. McQuaid, Blake L. Neubauer, Vincent P. Rocco
  • Angiotensin II antagonists
    Patent number: 5612360
    Abstract: This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: April 20, 1993
    Date of Patent: March 18, 1997
    Assignee: Eli Lilly and Company
    Inventors: Donald B. Boyd, Sherryl L. Lifer, Winston S. Marshall, Alan D. Palkowitz, William Pfeifer, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, K. Jeff Thrasher, Venkatraghavan Vasudevan, Celia A. Whitesitt
  • Process for preparation of benzo[f]quinolinones
    Patent number: 5578724
    Abstract: A series of benzoquinolin-3-ones are pharmaceuticals effective in treating conditions consequent on both Type I and Type II 5.alpha.-reductase and their preparation is disclosed.
    Type: Grant
    Filed: September 20, 1994
    Date of Patent: November 26, 1996
    Assignee: Eli Lilly and Company
    Inventors: Kevin L. Haehl, Thomas J. Kress, James P. Wepsiec
  • Angiotensin II antagonists
    Patent number: 5571925
    Abstract: This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: January 19, 1994
    Date of Patent: November 5, 1996
    Assignee: Eli Lilly and Company
    Inventors: Sherryl L. Lifer, Winston S. Marshall, Fariborz Mohamadi, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, Celia A. Whitesitt
  • Angiotensin II antagonists
    Patent number: 5569768
    Abstract: This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: October 29, 1996
    Assignee: Eli Lilly and Company
    Inventors: Donald B. Boyd, Sherryl L. Lifer, Winston S. Marshall, Alan D. Palkowitz, William Pfeifer, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, K. Jeff Thrasher, Venkatraghavan Vasudevan, Celia A. Whitesitt
  • Angiotensin II antagonists
    Patent number: 5563278
    Abstract: This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: October 8, 1996
    Assignee: Eli Lilly and Company
    Inventors: Sherryl L. Lifer, Winston S. Marshall, Fariborz Mohamadi, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, Celia A. Whitesitt
  • Angiotensin II antagonist intermediates
    Patent number: 5556981
    Abstract: This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: September 17, 1996
    Assignee: Eli Lilly and Company
    Inventors: Donald B. Boyd, Sherryl L. Lifer, Winston S. Marshall, Alan D. Palkowitz, William Pfeifer, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, K. Jeff Thrasher, Venkatraghaven Vasudevan, Celia A. Whitesitt
  • Benzo(F)quinolinones
    Patent number: 5541190
    Abstract: This invention relates to hexa- and octahydrobenzo[f]quinolin-3-ones, pharmaceutical formulations containing those compounds and methods of their use as steroid 5.alpha.-reductase inhibitors.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: July 30, 1996
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Kenneth S. Hirsch, Charles D. Jones, David E. Lawhorn, Loretta A. McQuaid, Leland O. Weigel